Upadacitinib - AbbVie

Drug Profile

Upadacitinib - AbbVie

Alternative Names: ABT-494; Upadacitinib tartrate

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Atopic dermatitis

Most Recent Events

  • 17 Feb 2018 Efficacy and adverse events data from a phase IIb trial in Atopic dermatitis presented at the 2018 American Academy of Dermatology Annual Meeting (AAD-2018)
  • 17 Feb 2018 AbbVie plans registration-enabling studies in Ulcerative colitis, Giant cell arteritis in 2018
  • 16 Feb 2018 Updated efficacy and adverse events data from a phase II CELEST trial in Crohn's disease released by AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top